For research use only. Not for therapeutic Use.
Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis[1].
Ravulizumab exhibits high-affinity binding to C5 and inhibits C5a and C5b formation, thereby preventing immune activation and hemolysis[1].
| Catalog Number | I042227 |
| CAS Number | 1803171-55-2 |
| Purity | ≥95% |
| Reference | [1]. Lee JW, et, al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019 Feb 7;133(6):530-539. |
